LEPR and Alzheimer disease: In a murine model of AD crossed with a diabetes model of leptin receptor deficiency (db/db), oral SGLT2i empagliflozin therapy was associated with a significant reduction in AD pathology, including the amyloid plaque density and soluble Aβ levels.